FDA approves Sanofi's diabetes drug Toujeo

February 26, 2015 1:54 AM

5 0

(Reuters) - U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.

The Food and Drug Administration approved the once daily, long-acting basal insulin to treat adults with both type 1 and the far more prevalent type 2 diabetes.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page